Abstract
Objectives Impairment of type I interferon (IFN-I) immunity has been reported in critically ill COVID-19 patients. This defect can be explained by the presence of circulating autoantibodies against IFN-I. We set out to improve the detection and the quantification of such antibodies (Abs) in a cohort of severe Covid-19 patients, in an effort to better document the prevalence of these Abs as the pandemics evolves and how they correlate with the clinical course of the disease.
Methods Anti-IFN-α Abs was investigated 84 critical COVID-19 patients who were admitted to ICU at the Lyon University Hospital, France with a commercially available kit (Thermo-Fisher).
Results Twenty-one patients out of 84 (25%) had anti-IFNα2 Ab above cut-off (>34ng/mL) in sera. A neutralizing activity against IFN-α2 was evidenced in 15 of them, suggesting that 18% of patients were positive for neutralizing anti-IFN-α and -ω auto-Abs. In addition, in most of patients with neutralizing IFN-I Abs, we noticed an impairment of the IFN-I response. However, we did not find any difference in terms of clinical characteristics or outcome between critical COVID-19 patients “with or without” neutralizing anti-IFN-α2 auto-Abs in these conditions. Finally, we detected anti-type I IFN auto-Abs in COVID-19 patients’ sera were detected throughout the ICU stay.
Conclusions We report that 18% of severe COVID-19 patients were positive for these Anti-Type-I IFN Abs, confirming the detrimental role of these Abs on the antiviral response. Our results further support the use of recombinant type I IFNs not targeted by the auto-Abs (e.g., IFN-b) in COVID-19 patients with an impaired IFN-I response.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04341142
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/33234651/
Funding Statement
This research is being supported by Hospices Civils de Lyon and by Fondation des Hospices Civils de Lyon.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Concerning severe COVID-19 patients, this study was registered to the French National Data Protection Agency under the number 20-097 and was approved by an ethical committee for biomedical research (Comite de Protection des Personnes HCL) under the number 20-41. In agreement with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law number 78-17 on 06/01/1978 and Decret number 2019-536 on 29/05/2019), we obtained consent from each patient or his next of kin.
Concerning mild COVID-19 patients, written informed consent was obtained from all participants; ethics approval was obtained from the national review board for biomedical research in April 2020 (Comite de Protection des Personnes Sud Mediterranee I, Marseille, France; ID RCB 2020-A00932-37), and the study was registered on ClinicalTrials.gov (NCT04341142).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest : All authors declare no conflict of interest
Funding : This research is being supported by Hospices Civils de Lyon and by Fondation des Hospices Civils de Lyon.
Data Availability
The data that support the findings of this study are available from the corresponding author, STA, upon reasonable request.